Diversified Trust Co Acquires 544 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Diversified Trust Co increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 23.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,874 shares of the biopharmaceutical company's stock after acquiring an additional 544 shares during the quarter. Diversified Trust Co's holdings in Regeneron Pharmaceuticals were worth $1,823,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the stock. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares during the period. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $28,000. Rakuten Securities Inc. increased its stake in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares during the last quarter. Finally, Tompkins Financial Corp acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $32,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 1.9%

NASDAQ:REGN traded up $9.99 during trading hours on Tuesday, reaching $534.99. The company had a trading volume of 873,892 shares, compared to its average volume of 900,522. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. The firm has a market cap of $57.76 billion, a price-to-earnings ratio of 13.67, a P/E/G ratio of 1.91 and a beta of 0.31. The business's 50-day simple moving average is $553.45 and its two-hundred day simple moving average is $629.75.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the prior year, the business earned $9.55 earnings per share. The business's quarterly revenue was down 3.7% on a year-over-year basis. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.66%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Analyst Upgrades and Downgrades

REGN has been the topic of several research analyst reports. Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. UBS Group decreased their target price on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research note on Thursday, June 5th. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a research report on Monday, June 2nd. Finally, The Goldman Sachs Group dropped their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $822.58.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.